The Bristol-Myers Squibb-Pfizer Alliance welcomes the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis Patents

The Bristol-Myers Squibb-Pfizer Alliance issued the following statement: We welcome the decision by the Court of Appeals for the Federal Circuit’s to affirm the U.S. District Court’s August 2020 decision finding the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9.326,945) covering Eliquis valid and infringed.

Given today’s decision, the earliest that generic manufacturers are permitted to launch their apixaban products is April 1, 2028, subject to additional appeals and challenges.